论文部分内容阅读
肝细胞癌(hepatocellular carcinoma,HCC)是全球最难治疗的恶性肿瘤之一,每年的发病率超过74.8万人,早期肝细胞癌可通过手术切除、原位肝移植或局部消融达到治愈,但是患者往往发现时已是肝细胞癌晚期,因此不适宜用外科切除或介入手段。分子靶向药具有特异性高、不良反应轻微等特点,目前在恶性肿瘤个体化治疗中扮演重要角色。索拉菲尼作为首个可用于临床治疗晚期HCC的分子靶向药物,近年来所获得临床效果不可忽视。本文就分子靶向药物在肝细胞癌治疗中的最新应用进展以及联合经动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)在肝癌中的治疗作一综述。
Hepatocellular carcinoma (HCC) is one of the most difficult malignant tumors in the world with an annual incidence of over 748,000. Early hepatocellular carcinoma can be cured by surgical resection, orthotopic liver transplantation or local ablation. However, patients Often found to have advanced hepatocellular carcinoma, it is not appropriate to use surgical excision or intervention. Molecular targeted drugs with high specificity, minor adverse reactions and other characteristics, the current individualized treatment of malignant tumors play an important role. As the first molecularly targeted drug that can be used in clinical treatment of advanced HCC, sorafenib can not be ignored in recent years. This article reviews the recent advances in the use of molecular targeted drugs in the treatment of hepatocellular carcinoma and the treatment of hepatocellular carcinoma with transcatheter arterial chemoembolization (TACE).